Navigation Links
ULURU Inc. Receives Notice From NYSE Amex Regarding Continued Listing Standards
Date:12/9/2011

ADDISON, Texas, Dec. 9, 2011 /PRNewswire/ -- ULURU Inc. (NYSE AMEX: ULU), a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, today announced that the Company has received notice from the NYSE Amex (the "Exchange"), dated December 5, 2011, indicating that the Exchange has accepted the Company's plan of compliance and granted the Company an extension until March 21, 2013 to regain compliance with the continued listing standards of Section 1003(a)(iii) of the Exchange's Company Guide.  Previously, the Company had received notice from the Exchange, dated September 21, 2011, that the Company was below the Exchange's stockholders' equity continued listing standards and did not meet the provisions of Section 1003(a)(iii) since the Company reported stockholders' equity of less than $6,000,000 at June 30, 2011 and has incurred losses from continuing operations and/or net losses in its five most recent fiscal years ended December 31, 2010.  The Company will be subject to periodic review by Exchange Staff during the extension period.  Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the extension period could result in the Company being delisted from the Exchange.

The notice from the Exchange also indicated that the Company is not in compliance with an additional listing standard as set forth in Part 10 of the Exchange's Company Guide.  A review by the Exchange Staff of the Company's Form 10-Q for the period ended September 30, 2011, indicated that the Company does not meet the provisions of Section 1003(a)(iv) since the Company has sustained losses which are so substantial in relation to its overall operations or its existing financial resources, or its financial condition has become so impaired that it appears questionable, in the opinion of the Exchange, as to whether the Company will be able to continue operations and/or meet its obligations as they mature.

The Company was afforded the opportunity to submit a plan of compliance to the Exchange by January 5, 2012, that demonstrates the Company's ability to regain compliance with Section 1003(a)(iv) of the Company Guide by April 2, 2012.  If the Company does not submit a plan of compliance, or if the plan is not accepted by the Exchange, the Company will be subject to delisting procedures as set forth in Section 1010 and part 12 of the Company Guide. 

The Company believes it can provide the Exchange with a satisfactory plan by January 5, 2012, to show that it will be able to return to compliance with Section 1003(a)(iv) of the Exchange's Company Guide.

While the notifications from the Exchange does not affect the current listing of the Company's common stock, the Company's failure to submit a plan of compliance with Section 1003(a)(iv) by January 5, 2012, or the failure of the Exchange to accept any plan of compliance submitted, are likely to result in the Company no longer being listed on the NYSE Amex.

About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal delivery system.  For further information about ULURU Inc., please visit our website at www.ULURUinc.com.  For further information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended.  These statements are subject to numerous risks and uncertainties, including but not limited to ULURU's compliance with the continued listing standards of the NYSE Amex, the Company's ability to make progress with the plan of compliance, the submission of a plan of compliance by ULURU and the acceptance of such plan of compliance by the NYSE Amex, the Company's ability to maintain its NYSE Amex listing, and to risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Reports Third Quarter 2011 Financial Results
2. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2011 and to Provide a Business Update
3. ULURU Inc. Announces Altrazeal® Agreement for the European Market
4. ULURU Inc. Receives NYSE Amex Notice of Non-Compliance with Continued Listing Standards
5. ULURU Inc. Enters Into Strategic Financings of Up to $1.6 Million at a Premium to Current Share Price
6. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Second Quarter Ended June 20, 2011 and to Provide a Business Update
7. ULURU Inc. Announces Reverse Stock Split
8. ULURU Inc. Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor
9. ULURU Inc. Announces Voting Results of Reconvened Annual Meeting of Stockholders
10. ULURU Inc. Raises $140,000 in Convertible Debt Offering
11. ULURU Inc. Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Health and Gateway Health proudly announce a dynamic collaboration that ... plan members with specific high risk needs. In ... group of consumers, Wellbridge combines technology and population expertise with ... members, daily behaviors and lifestyle. ... , , ...
(Date:12/5/2016)...  New research by the CVS Health (NYSE: ... U.S. Department of Health and Human Services, Office ... (ASPR), published online today in JAMA Internal ... patients with chronic conditions to refill medications prior ... affirms that public-private partnerships can facilitate timely pharmacy ...
(Date:12/5/2016)... 5, 2016  BD (Becton, Dickinson and Company) (NYSE: ... company, will demonstrate an enhanced technology platform designed with ... the company,s leading Pyxis™ and Alaris™ systems, at this ... Midyear Meeting being held in Las ... national data show that approximately 68 percent of medication ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... 03, 2016 , ... Penrose Senior Care Auditors® was announced ... evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony and Banquet ... for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ingenuity, commitment ...
(Date:12/4/2016)... , ... December 04, 2016 , ... ... major cosmetic surgery can now take advantage of a cosmetic procedure known as ... rejuvenation treatment that reduces the appearance of age spots, fine lines, uneven ...
(Date:12/4/2016)... PITTSBURGH, PA (PRWEB) , ... December 04, 2016 , ... ... not enough. One must brush properly to achieve optimal results. This important necessity inspired ... saw a need for a way to ensure that people break or avoid bad ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in ... Conference Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New ... Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and ...
(Date:12/2/2016)... DIEGO, Calif. (PRWEB) , ... December 02, 2016 , ... ... Event at the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight individuals ... myeloproliferative neoplasms (MPNs) by going above and beyond the standard of care, demonstrating leadership ...
Breaking Medicine News(10 mins):